Current Landscape and Future Direction of PD-1/PD-L1 Checkpoint Inhibitors in Cancer Treatment

Simona Serratì; Francesca Margheri

doi:10.3390/biom13081209

Current Landscape and Future Direction of PD-1/PD-L1 Checkpoint Inhibitors in Cancer Treatment

Biomolecules. 2023 Aug 1;13(8):1209. doi: 10.3390/biom13081209.

Authors

Simona Serratì¹, Francesca Margheri²

Affiliations

¹ Laboratory of Experimental Pharmacology, IRCCS Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy.
² Department of Experimental and Clinical Biomedical Sciences, University of Florence, 50134 Florence, Italy.

Abstract

Immune checkpoints are involved in controlling the activation or inhibition of the immune response and are associated with receptors on the immune cell surface [...].

Publication types

Editorial

MeSH terms

B7-H1 Antigen*
Cell Membrane
Humans
Immune Checkpoint Inhibitors / pharmacology
Immune Checkpoint Inhibitors / therapeutic use
Neoplasms* / drug therapy
Programmed Cell Death 1 Receptor

Substances

B7-H1 Antigen
Programmed Cell Death 1 Receptor
Immune Checkpoint Inhibitors